Therefore, we studied a differentiated subset of cells termed Th17, which have emerged as key mediators of autoimmunity and inflammation for their potential implication in toxicity and responses after anti-CTLA4 therapy. The gene discussed is CTLA4; the disease is Autoimmunity.